- We're Not Greece: Italian Prime Minister Monti
- Private Homebuilders in the US: Dead Men Walking
- Dividend Payout Could Hit Record Amount This Year
- With Investors So Bullish, Stock Pullback Must Be Ahead
- Is Bill Gross, PIMCO's Bond King, Losing His Touch?
- Why Saving Greece Could Destroy the World
- Apple’s Record Run: $500 Is a Magic Number
- Housing Still Hurting Consumers, Economy: Bernanke
- Get Ready for $5 Gas This Year: Ex-Shell CEO
- In Search of America's ‘Hottest Forecasters’
- Dow vs. S&P 500: Which is a Better Investment?
- Mick Fleetwood on the MP3 ‘Dumbing Down’ of Music
- Avis on the Road to Strong Growth: Analyst
- Private Homebuilders: Dead Men Walking
- LinkedIn’s Growth Is Already Priced In: Analyst
- The Real Reason Behind Bank of America’s Rally
- 5 Hedge Funds’ Top Stocks Soar After 2011 Rout
- This Valentine’s Day Love Is Served on a Silver Platter
MOST SHARED
- US Stocks Avoid Closing Down Over 1%, Again
- When Love and the Fed Collide
- How Rescuing Greece Could Destroy the World
- Commodities Next Week: Why Gas Prices Are Heading Toward $5 Per Gallon
- 2012: The Year of the Stock Picker
- Get Ready for $5 Gas This Year: Ex-Shell CEO
- Pauley Perrette's Southern Bakery a Hit in Manhattan
- Private Homebuilders: Dead Men Walking
- Why Greece Will Default, Leave the Euro Zone
- Apple’s Record Run: $500 Is a Magic Number
MOST POPULAR
HOT ON FACEBOOK
Did Martha Stewart Miss Big Payout on ImClone?
Text Size 
Did Martha Stewart miss out on a big payday on ImClone stock?
 |
Frank Franklin Ii / AP |
Bristol-Myers Squibb's [BMY
Loading...
()
] proposal to buy ImClone Systems [IMCL
Loading...
()
] for $4.5 billion brings back memories of the 2002 insider trading scandal that landed the domestic diva in jail and made ImClone a household word.
Stewart, who sold her ImClone stock in 2001—allegedly on a tip from ImClone founder Sam Waksal—got $58.43 a share, or a total of $229,513. She ended up being convicted in 2004 of lying to federal prosecutors about the circumstances surrounding the sale and spent five months in prison.
Now, Bristol-Myers Squibb is offering $60 for ImClone, so if Stewart had held onto her stock, she would've made a paltry $6,000 more seven years later.
But if she had waited until June 2004, when ImClone shares rose as high as $87, the payout would have been $112,223 more.
Stewart sold her stock allegedly on worries that the Food and Drug Administration was going to reject Erbitux, ImClone's colon cancer drug. Ironically, ImClone recently received positive reviews for the drug's efficacy on colon cancer and head and neck cancer. It is in the late stage of testing its effects on pancreatic cancer and may soon file with the FDA to investigate its effects on lung cancer.
What's more, former CEO Sam Waksal, who pleaded guilty to six criminal charges of perjury, securities fraud, bank fraud and obstruction of justice in August 2002, finishes his seven years and three months in prison next week.
- Marketing clichés aside, sometimes diamonds are for investing.
- The ‘Fast Money’ traders weigh in on fashion related stocks from apparel to footwear.
- This list of the 10 most active cities for speed traps was compiled by Trapster.com. See if your town is there.
- This Valentine’s Day should prove a love fest for restaurants, as many couples will be dining out.
- Here’s a look at Westminster Kennel Club’s most successful breeds—and how much they cost.
- What kind of homes do celebrity couples share? Here’s our updated list. Take a look.
Data is a real-time snapshot *Data is delayed at least 15 minutes
